Sarepta Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hey, everybody. It's Alethia Young here. I cover large-cap, small, mid-cap at Cantor, biotech, of course. Very happy to have Sarepta Therapeutics. I have Doug Ingram, who's the President and CEO and Ian Estepan, who's the EVP and CFO. So obviously, you guys issued a press release this morning on 5051, so it was exciting to me at least. So let's start with that. Just give us the highlights of that release. And then, it also just seems like maybe a positive on the faster pathway to market and it seems like it was a little bit ahead of what I thought was the scheduled time for this. So maybe we start with there?
Sure, Alethia. First, thank you for having us today. We're really excited to talk about the progress we're making. And we are also very excited about that press release this morning. I think I've said before, this broad strokes, we have been -- while
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
